Company Filing History:
Years Active: 2008
Title: Boris Perlmutter: Pioneer in Protein Kinase Inhibition
Introduction
Boris Perlmutter is an innovative inventor based in Lod, Illinois. He holds a notable patent in the field of biochemistry, specifically relating to protein kinase inhibitors. His work contributes significantly to the advancement of medical and pharmaceutical sciences.
Latest Patents
Boris Perlmutter's patent, titled "Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics," describes groundbreaking small molecules that have a high affinity for the ATP binding site of protein kinases. These molecules are designed to be conjugated with a peptide or peptidomimetic that mimics the substrate of the Protein Kinase B (PKB). This innovative approach leads to chimeric compounds that serve as PKB inhibitors, offering improved activity and selectivity. The patent also details the utility of novel ATP mimetic compounds, particularly isoquinoline derivatives, as inhibitors of protein kinases for various applications, including medical and drug design purposes. Furthermore, it highlights the potential of these inhibitors in treating conditions such as cancers, diabetes, cardiovascular diseases, hemorrhagic shock, obesity, inflammatory diseases, and even disorders of the central nervous system and autoimmune diseases.
Career Highlights
Boris is associated with Curegenics Ltd., a company focused on innovative biotechnological solutions. His contributions in the realm of protein kinase inhibition are essential in driving forward therapeutic avenues for numerous diseases.
Collaborations
Boris collaborates with eminent colleagues Nurit Livnah and Tamar Yechezkel. Together, they work towards enhancing the effectiveness of protein kinase inhibitors and exploring their extensive applications in healthcare.
Conclusion
Boris Perlmutter stands out as a significant figure in the field of biochemistry, particularly in the development of novel protein kinase inhibitors. His innovative work at Curegenics Ltd. not only advances scientific knowledge but also has the potential to lead to groundbreaking treatments for complex diseases.